Published in:
01-08-2021 | NSCLC | Publisher Correction
Correction to: Gastroparesis Following Immune Checkpoint Inhibitor Therapy: A Case Series
Published in: Digestive Diseases and Sciences | Issue 8/2021
Login to get accessExcerpt
The original version of the article unfortunately contained an error in the Table 2. In the column ‘Motility immune-related adverse event’ of Table 2, the term ‘Intestinal pseudo-obstruction’ was inadvertently removed in the final version. Corrected Table 2 is given below.
Table 2
Prior case reports of patients with gastrointestinal Motility immune-related adverse event
|
Motility immune-related adverse event
|
Age, years
|
Gender
|
ICI
|
Target
|
Tumor
|
References
|
|---|---|---|---|---|---|---|
|
Intestinal pseudo-obstruction
|
57
|
Male
|
Pembrolizumab
|
PD-1
|
Neuroendocrine
|
[17]
|
|
62
|
Male
|
Nivolumab
|
PD-1
|
NSCLC
|
[35]
|
|
|
71
|
Female
|
Pembrolizumab
|
PD-1
|
GEJ carcinoma
|
[25]
|
|
|
Constipation
|
62
|
Male
|
Ipilimumab
|
CTLA-4
|
Melanoma
|
[20]
|
|
Ileus
|
66
|
Male
|
Ipilimumab + nivolumab
|
CTLA-4 +PD-1
|
Merkel cell carcinoma
|
[19]
|